IDH1 and neoplasm: Chuntova et al. have further demonstrated that treatment of mice that harbor HLA-A2/HLA-DR1-syngeneic IDH1R132H tumor cells with the IDH mutant inhibitor (AG-881) suppressed the progression of IDH1R132H glioma.